Dasatinib followed by second allogeneic hematopoietic stem cell transplantation for relapse of Philadelphia chromosome-positive acute lymphoblastic leukemia after the first transplantation

International Journal of Hematology

Volumn 92, Issue 3, 2010, Pages 542-546

  Ishida, Yoko ^a   Terasako, Kiriko ^a   Oshima, Kumi ^a   Sakamoto, Kana ^a   Ashizawa, Masahiro ^a   Sato, Miki ^a   Kikuchi, Misato ^a   Kimura, Shun Ichi ^a   Nakasone, Hideki ^a   Okuda, Shinya ^a   Kako, Shinichi ^a   Yamazaki, Rie ^a   Nishida, Junji ^a   Kanda, Yoshinobu ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Dasatinib; Hematopoietic stem cell transplantation; Philadelphia chromosome positive acute lymphoblastic leukemia

Indexed keywords

BCR ABL PROTEIN; CD19 ANTIGEN; CD79A ANTIGEN; CEFEPIME; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; DASATINIB; ETOPOSIDE; FLUDARABINE; GANCICLOVIR; HLA DR ANTIGEN; IMATINIB; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; PREDNISOLONE;

ABDOMINAL PAIN; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; APOPTOSIS; ARTICLE; BLAST CELL; BLOOD EXAMINATION; BLOODY DIARRHEA; BONE MARROW CELL; CASE REPORT; CHROMOSOME ANALYSIS; CONTINUOUS INFUSION; CYTOMEGALOVIRUS ANTIGENEMIA; CYTOMEGALOVIRUS INFECTION; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TOLERANCE; DRUG WITHDRAWAL; FEMALE; FEVER; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEADACHE; HEMATURIA; HEMORRHAGIC CYSTITIS; HLA MATCHING; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKOCYTOSIS; LYMPHOCYTIC INFILTRATION; MYALGIA; NAUSEA; PHILADELPHIA 1 CHROMOSOME; PHILADELPHIA CHROMOSOME POSITIVE CELL; POLLAKISURIA; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT DURATION; VOMITING; WHOLE BODY RADIATION;

ADOLESCENT; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RECURRENCE; REMISSION INDUCTION; THIAZOLES; TRANSPLANTATION, HOMOLOGOUS;

EID: 78549294155     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-010-0678-6     Document Type: Article

References (16)

1. Ottmann OG, Pfeifer H. Management of Philadelphia chromosome-positive acute lymphoblastic leukemia (ph+ all). Hematol Am Soc Hematol Educ Program. 2009;371-81.
2. M Yanada T Naoe H Iida H Sakamaki T Sakura H Kanamori, et al. 2005 Myeloablative allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: significant roles of total body irradiation and chronic graft-versus-host disease Bone Marrow Transplant 36 867 872 1:STN:280:DC%2BD2MrnvVejug%3D%3D 10.1038/sj.bmt.1705148 16113659 (Pubitemid 41655612)
3. HJ Khoury F Guilhot TP Hughes DW Kim JE Cortes 2009 Dasatinib treatment for Philadelphia chromosome-positive leukemias: practical considerations Cancer. 115 1381 1394 1:CAS:528:DC%2BD1MXksF2ru7g%3D 10.1002/cncr.24155 19195046
4. O Ottmann H Dombret G Martinelli B Simonsson F Guilhot RA Larson, et al. 2007 Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study Blood 110 2309 2315 1:CAS:528:DC%2BD2sXhtFCnsbzK 10.1182/blood-2007-02-073528 17496201 (Pubitemid 47523149)
5. M Yanada J Takeuchi I Sugiura H Akiyama N Usui F Yagasaki, et al. 2006 High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group J Clin Oncol 24 460 466 1:CAS:528:DC%2BD28XhsFSku7c%3D 10.1200/JCO.2005.03.2177 16344315 (Pubitemid 46630465)
6. K Oshima Y Kanda H Nakasone S Arai N Nishimoto H Sato, et al. 2008 Decreased incidence of acute graft-versus-host disease by continuous infusion of cyclosporine with a higher target blood level Am J Hematol 83 226 232 1:CAS:528:DC%2BD1cXjsFyksr8%3D 10.1002/ajh.21087 17918253 (Pubitemid 351303948)
7. Y Kanda S Mineishi T Saito A Saito M Ohnishi H Niiya, et al. 2002 Response-oriented preemptive therapy against cytomegalovirus disease with low-dose ganciclovir: a prospective evaluation Transplantation. 73 568 572 1:CAS:528:DC%2BD38Xitlyqt7w%3D 10.1097/00007890-200202270-00015 11889432
8. F Fei Y Yu A Schmitt MT Rojewski B Chen J Greiner, et al. 2008 Dasatinib exerts an immunosuppressive effect on CD8+ T cells specific for viral and leukemia antigens Exp Hematol 36 1297 1308 1:CAS:528:DC%2BD1cXhtFylsLjP 10.1016/j.exphem.2008.05.002 18619726
9. E Jabbour J Cortes H Kantarjian S Giralt BS Andersson F Giles, et al. 2007 Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity Cancer. 110 340 344 1:CAS:528: DC%2BD2sXos1yrt78%3D 10.1002/cncr.22778 17559140 (Pubitemid 47121894)
10. M Breccia F Palandri AP Iori E Colaci R Latagliata F Castagnetti, et al. 2010 Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib Leuk Res. 34 143 147 1:CAS:528:DC%2BC3cXhtlGgt78%3D 10.1016/j.leukres.2009.04. 036 19481800
11. A Shimoni M Leiba M Schleuning G Martineau M Renaud M Koren-Michowitz, et al. 2009 Prior treatment with the tyrosine kinase inhibitors dasatinib and nilotinib allows stem cell transplantation (SCT) in a less advanced disease phase and does not increase SCT toxicity in patients with chronic myelogenous leukemia and Philadelphia positive acute lymphoblastic leukemia Leukemia. 23 190 194 1:CAS:528:DC%2BD1MXkvVeisg%3D%3D 10.1038/leu.2008.160 18596746
12. A Quintas-Cardama H Kantarjian F Ravandi S O'Brien D Thomas G Vidal-Senmache, et al. 2009 Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy Cancer. 115 2482 2490 1:CAS:528:DC%2BD1MXmvVyhs7Y%3D 10.1002/cncr.24257 19280591
13. Ravandi F, O'Brien S, Thomas D, Faderl S, Jones D, Garris R, et al.: First report of phase II study of dasatinib with hyperCVAD for the frontline treatment of patients with Philadelphia chromosome positive (ph+) acute lymphoblastic leukemia. Blood (in press).
14. A Quintas-Cardama X Han H Kantarjian J Cortes 2009 Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia Blood 114 261 263 1:CAS:528:DC%2BD1MXovVKmu7w%3D 10.1182/blood-2008-09-180604 19414863
15. LJ Christopher D Cui C Wu R Luo JA Manning SJ Bonacorsi, et al. 2008 Metabolism and disposition of dasatinib after oral administration to humans Drug Metab Dispos 36 1357 1364 1:CAS:528:DC%2BD1cXotVensr4%3D 10.1124/dmd.107.018267 18420784 (Pubitemid 351929320)
16. S Mustjoki M Ekblom TP Arstila I Dybedal PK Epling-Burnette F Guilhot, et al. 2009 Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy Leukemia. 23 1398 1405 1:CAS:528:DC%2BD1MXpvF2kurs%3D 10.1038/leu.2009.46 19295545